© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Beta Bionics, Inc. (BBNX) stock declined over -4.66%, trading at $10.65 on NASDAQ, down from the previous close of $11.17. The stock opened at $11.01, fluctuating between $10.60 and $11.40 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 27, 2026 | 11.01 | 11.40 | 10.60 | 10.65 | 605.76K |
| Apr 23, 2026 | 12.22 | 12.22 | 11.15 | 11.43 | 1.28M |
| Apr 22, 2026 | 12.96 | 12.99 | 10.91 | 12.20 | 2.31M |
| Apr 21, 2026 | 13.03 | 13.09 | 11.84 | 12.27 | 981.39K |
| Apr 20, 2026 | 13.10 | 13.35 | 12.79 | 12.91 | 1.36M |
| Apr 17, 2026 | 12.50 | 13.13 | 12.28 | 12.98 | 1.58M |
| Apr 16, 2026 | 13.02 | 13.32 | 11.99 | 12.18 | 1.6M |
| Apr 14, 2026 | 10.50 | 11.85 | 10.50 | 11.81 | 1.2M |
| Apr 13, 2026 | 8.88 | 10.65 | 8.88 | 10.63 | 1.21M |
| Apr 10, 2026 | 9.63 | 9.71 | 8.80 | 8.86 | 2.01M |
| Apr 09, 2026 | 9.67 | 10.03 | 9.53 | 9.63 | 829.44K |
| Apr 08, 2026 | 10.10 | 10.30 | 9.47 | 9.79 | 983.64K |
| Apr 07, 2026 | 9.93 | 10.12 | 9.57 | 9.73 | 631.2K |
| Apr 06, 2026 | 9.93 | 10.09 | 9.80 | 9.95 | 478.86K |
| Apr 02, 2026 | 9.81 | 10.28 | 9.69 | 9.93 | 611.99K |
| Apr 01, 2026 | 10.13 | 10.49 | 9.96 | 10.01 | 793.83K |
| Mar 31, 2026 | 9.93 | 10.40 | 9.37 | 10.02 | 2.04M |
| Mar 30, 2026 | 10.76 | 10.92 | 9.70 | 9.86 | 1.63M |
| Mar 27, 2026 | 11.28 | 11.45 | 10.73 | 10.76 | 812.48K |
| Mar 25, 2026 | 11.43 | 11.92 | 11.16 | 11.31 | 723.39K |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
| Employees | 352 |
| Beta | 5.6 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 62.143% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Medical - Equipment & Services |